CD274 and ovarian carcinoma: While PD-(L)1 inhibitors did not show survival benefits as a single agent or in combination with chemotherapy in patients with recurrent ovarian cancer in phase 3 clinical trials,43–47 this is hypothesized to have resulted from the more highly immunosuppressive tumor microenvironment in the recurrent setting than that in the chemonaïve setting.48